The private equity fund Polaris has acquired a majority stake in Salfarm, a Danish player within animal pharmaceuticals. Subsequently, Polaris has also acquired the Finnish distributor of animal pharmaceuticals, FaunaPharma, thereby strengthening its presence in the Finnish market.
Salfarm was formed in 1979 and has grown to become a leading Danish player within animal pharmaceuticals. Salfarm is a distributor and Nordic marketing authorisation holder for vaccines, medicines and medical accessories for farm and companion animals. Delivering a double-digit annual revenue growth rate over the past ten years, Salfarm has established a strong presence across the Nordic countries.
Headquartered in Kolding, Denmark, Salfarm employs around 30 people and owns subsidiaries in Sweden and Norway. Peter Wendorff Olsen, CEO of Selfarm, will reinvest alongside the other members of the management.
Polaris invests in well-established medium-sized companies in the Nordic countries and has, to date, invested in more than 50 companies and made more than 100 add-on investments in portfolio companies. Polaris owns 16 companies with total revenue of approximately DKK 8bn and more than 7,000 employees.
Accura advised Polaris in connection with the transactions.